Alex Zevin, PhD, of @fredhutch put Countable PCR to work across 9 labs: linear response over 6 orders of magnitude and fusion detection from 55 pg of RNA.
~30M compartments. Every molecule counted directly.
Via @genbio: https://t.co/LYOO8M5hEC
#PCR#Genomics#CountablePCR
Unlock the power of digital PCR! Join our free GEN webinar on June 18 to explore applications and challenges in research and clinical labs. Register now: https://t.co/9MSYM0oe8J #PCR#Genomics#ClinicalLabs
ποΈ Todayβs the last day to register for #AMP2026 at the standard registration rate. Register by 11:59 p.m. Eastern to save.
Donβt wait until itβs too late!
Register: https://t.co/WEMBt9mIFE
Join us at the @DrugDiscovNews Live Symposium, Nov 17β18, where Samir Afif, PhD, will share how Countable #PCR's single-molecule analysis reveals what titer can miss.
Register: https://t.co/2gHSVeqT3e
Also speaking: experts from @Stanford, @biotechne, @UCSanDiego, and more.
Meet Countable Labs at #AMP2026! π¬
Discover single-molecule #PCR for BCR::ABL1, KMT2A, NPM1 & methylation at Booth #943.
π 4 posters
π€ Live demos
π€ Workshop with @fredhutch, @UTMDAnderson & HematoLogics
Learn more: https://t.co/JDQpn9aJtM
@AMPath
What's next for #PCR?
Join Wim Trypsteen, PhD, and Gordon Janaway, PhD, on Oct. 28 for a @GenomeWeb webinar exploring #dPCR reproducibility, standardization, and next-gen PCR with direct #singlemoleculecounting across 30M+ compartments.
Register now: https://t.co/6nJd7RvnXQ
Engage with our advocacy experts and other professionals working to address critical challenges in the field of molecular pathology by joining us at #AMP2026 in Seattle, Nov. 10β14.
Be a part of the change you want to see. Register: https://t.co/yGUinuEEKg
Broad coverage or deep sensitivity? In #leukemiatesting, you shouldn't have to choose.
Our on-demand workshop shows how single-molecule counting delivers both. https://t.co/xTjrEYNvIk
#PCR#MRD
Can leukemia testing deliver both broad coverage and deep MRD sensitivity? Watch this on-demand corporate workshop from @countablelabs to explore how single-molecule counting assays can help overcome this trade-off.
https://t.co/nCCQlWcEb3
Meet Ancora, our first clinical research assays for heme oncology, built on Countable PCR.
Sensitive to residual disease. Tighter CVs than conventional RT-PCR. Multiplexed, high-throughput, low input.
Donβt just take our word for it β¬οΈ
Explore Ancora: https://t.co/71IjeaSked
𧬠New research in @MolTherapy highlights Countable PCR in the characterization of residual plasmid and host-cell DNA in AAV vectors.
Congratulations to Mojca Janc and David Dobnik on the publication!
Read the paper: https://t.co/36eakTsU2l
#GeneTherapy#CountablePCR
Missed our webinar with @AMPath? Catch it on demand: single-molecule counting PCR for MRD in CML and AML, no standard curves required.
Watch now: https://t.co/xTjrEYO3xS
#MRD#HemeOnc
One color doesn't have to mean one target.
Countable PCR combines chemistries into unique optical signatures, so targets can outnumber color channels.
HPV: multiple subtypes, one reaction
KMT2A: 18 fusions across 6 partners, one assay
More targets. More from every sample.
ποΈ What happens when you stop estimating and start counting?
Our founder and CTO, Christina Fan, PhD, spoke with Technology Networks about how Countable PCR is advancing quantitative molecular analysis.
Read the interview π https://t.co/EI7N0zM1oI
#CellAndGeneTherapy
Early detection remains one of the most effective tools against breast cancer. This October, we're standing with the patients, survivors, caregivers, and researchers working toward earlier answers. Get screened, know your baseline, and support the science. ποΈ
Digital PCR has moved from promising to proven. Proud to sponsor this @GenomeWeb webinar with Wim Trypsteen (University of Ghent) and our own Gordon Janaway, PhD. Oct 28, 11am ET.
Register: https://t.co/2g44MwKQug
Today's the day. Introducing Ancora: the new standard in molecular testing. More targets, more range, more certainty, all from a single reaction. Direct single-molecule counting. Fusion + co-mutation resolution. Results in as little as 3 hours. Learn more: https://t.co/Pf2j4FDDii
MRD monitoring in leukemia forces a compromise: broad coverage or sensitivity, rarely both. That's changing, and Thursday's webinar is only part of what we've got planned.
Don't miss it: https://t.co/PKHmzBLIZy
Countable Labs is proud to sponsor @tech_networks Advances in Drug Discovery & Development 2026.
This online symposium explores how AI, computational methods, and emerging technologies like CAR-T are reshaping drug discovery and development.
Join us: https://t.co/ECWIHYLtjm
September's cancer awareness calendar covers childhood cancer, leukemia, lymphoma, ovarian, prostate, and vaginal cancers.
Two hit closest to home for us:
ποΈ Childhood cancer: limited sample, full biology, no compromise
ποΈ Leukemia: consistent, trusted results guide next steps